Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | KDM4B | O94953 | 1/20 | 0.49 |
| ▸ | KDM5C | P41229 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.49 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.49 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 7/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1178698 | 0.77 | KDM4A (0.73) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL914338 | 0.74 | PDPK1 (0.59) | IP6K1PARP1PDPK1CA12ALOX15 | |
| SCHEMBL29837279 | 0.71 | — | — | |
| SCHEMBL89868 | 0.71 | — | — | |
| SCHEMBL2447581 | 0.69 | QPCT (0.50) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL2447586 | 0.69 | QPCT (0.50) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL27982386 | 0.69 | QPCT (0.50) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Hydrazine SCHEMBL3450713 | 0.68 | QPCT (0.49) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL9263181 | 0.68 | PARP1 (0.64) | IP6K1PARP1PDPK1SMN1; SMN2QPCT | |
| SCHEMBL27828038 | 0.68 | PIM1 (0.64) | PARP1SMN1; SMN2QPCTPPARGRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713484-B2 | FUSED RING PYRIMIDINE DERIVATIVES; LOW CYTOTOXICITY | WARNER-LAMBERT COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20030186987-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2003-10-02 | — | — | US | disclosed |
| US-6521620-B1 | Suppressing tumors, especially breast cancers; antiproli-ferative agents; arthritis, vascular restenosis, psoriasis and angiogenesis; extremely low cytotoxicity | WARNER-LAMBERT COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-6455534-B2 | ANTIPROLIVERATIVE, -CARCINOGENIC AND -TUMOR AGENTS; MITOGENESIS-ACTIVATED PROTEIN KINASE INHIBITORS; NONCYTOTOXIC; BINDING WITH HIGH AFFINITY AT THE ADENOSINE TRIPHOSPHATE BINDING SITE OF THE KINASES | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2001-10-04 | — | — | US | disclosed |
| US-6265410-B1 | ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6084095-A | INCLUDING 6-AMINO-4-(3-BROMOANILINO)PYRIDO(3,2-D)PYRIMIDINE; 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO (3,2-D)PYRIMIDINE; AND 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO(3,2-D)PYRIMIDINE; USEFUL IN TREATING PROLIFERATIVE DISEASES SUCH AS CANCER | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-5654307-A | ANTICARCINOGENIC AGENTS, ANTIARTHRITIC AGENT, SKIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0742717-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1995019774-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | KDM4A 2593/4885KDM4B 2106/4885KDM5C 1428/4885 |
| US-20030186987-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | KDM4A 2757/4885KDM4B 2281/4885KDM5C 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.